Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prognostic factors for work disability in patients with chronic widespread pain and fibromyalgia: protocol for a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Upper airway symptoms associate with the eosinophilic phenotype of COPD

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Characteristics and impact of exercise-induced laryngeal obstruction: an international perspective

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Collaborative tuberculosis/HIV activities in the European Region

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Silke van Koningsbruggen-Rietschel
  • Jane C Davies
  • Tacjana Pressler
  • Rainald Fischer
  • Gordon MacGregor
  • Scott H Donaldson
  • Knut Smerud
  • Nils Meland
  • Jann Mortensen
  • Marie Ø Fosbøl
  • Damian G Downey
  • Astrid H Myrset
  • Hugo Flaten
  • Philip D Rye
View graph of relations

Background: OligoG is a low molecular-weight alginate oligosaccharide that improves the viscoelastic properties of cystic fibrosis (CF) mucus and disrupts biofilms, thereby potentiating the activity of antimicrobial agents. The efficacy of inhaled OligoG was evaluated in adult patients with CF.

Methods: A randomised, double-blind, placebo-controlled multicentre crossover study was used to demonstrate safety and efficacy of inhaled dry powder OligoG. Subjects were randomly allocated to receive OligoG 1050 mg per day (10 capsules three times daily) or matching placebo for 28 days, with 28-day washout periods following each treatment period. The primary end-point was absolute change in percentage predicted forced expiratory volume in 1 s (FEV1) at the end of 28-day treatment. The intention-to-treat (ITT) population (n=65) was defined as randomised to treatment with at least one administration of study medication and post-dosing evaluation.

Results: In this study, 90 adult subjects were screened and 65 were randomised. Statistically significant improvement in FEV1 was not observed in the ITT population. Adverse events included nasopharyngitis, cough and pulmonary exacerbation. The number and proportions of patients with adverse events and serious adverse events were similar between OligoG and placebo group.

Conclusions: Inhalation of OligoG-dry powder over 28 days was safe in adult CF subjects. Statistically significant improvement of FEV1 was not reached. The planned analyses did not indicate a significant treatment benefit with OligoG compared to placebo. Post hoc exploratory analyses showed subgroup results that indicate that further studies of OligoG in this patient population are justified.

Original languageEnglish
JournalERJ Open Research
Volume6
Issue number4
Pages (from-to)00132-2020
ISSN2312-0541
DOIs
Publication statusPublished - Oct 2020

ID: 62064368